1990
Opioid antagonist challenges in buprenorphine maintained patients
Kosten T, Krystal J, Charney D, Price L, Morgan C, Kleber H. Opioid antagonist challenges in buprenorphine maintained patients. Drug And Alcohol Dependence 1990, 25: 73-78. PMID: 2323312, DOI: 10.1016/0376-8716(90)90144-4.Peer-Reviewed Original ResearchConceptsSublingual buprenorphine treatmentBlood pressure increaseDouble-blind placeboOpioid withdrawal symptomsBlind placeboIntravenous naloxoneNaltrexone challengeOral naltrexoneLast doseBlood pressureBuprenorphine treatmentPlacebo substitutionMHPG levelsWithdrawal symptomsPlacebo challengeSignificant symptomsAntagonist challengeBuprenorphinePatientsPlaceboNaloxoneSymptomsNaltrexoneDoseMonths
1989
Intermittent naloxone attenuates the development of physical dependence on methadone in rhesus monkeys
Krystal J, Walker M, Heninger G. Intermittent naloxone attenuates the development of physical dependence on methadone in rhesus monkeys. European Journal Of Pharmacology 1989, 160: 331-338. PMID: 2540995, DOI: 10.1016/0014-2999(89)90088-5.Peer-Reviewed Original ResearchConceptsOpiate withdrawal syndromeInjection of naloxoneWithdrawal syndromeTreatment periodNaloxone injectionNaloxone administrationWithdrawal responsePhysical dependenceDays of methadoneAntagonist exposureMethadone treatmentDaily injectionsLack of incrementReceptor mechanismsDrug combinationsNaloxoneRhesus monkeysSyndromeDay 16MethadoneSame monkeysManagement of situationsInjectionAdministrationDays